Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Eli Lilly Files Suit Against Six Firms Over Unauthorized Retatrutide Sales Eli Lilly and Company has filed lawsuits against six companies it accuses of illegally manufacturing, marketing, and selling retatrutide, an experimental obesity and metabolic drug that has not yet received approval from the...
Qatar's Health Ministry bans trading, use or promotion of unlicensed peptide products
Qatar Health Ministry Cracks Down on Unlicensed Peptide Products Qatar's Ministry of Public Health has issued a ban on the trading, use, and promotion of unlicensed peptide products, according to a report from The Peninsula Qatar.
What would it take to get peptides on the shelf?
What Would It Take to Get Peptides on the Shelf? NPR Report Spotlights Regulatory Crossroads for Booming Industry A recent NPR report poses a deceptively simple question that has become one of the most consequential regulatory puzzles in American health and wellness: what would it actually take to ...
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug Retatrutide, an experimental weight-loss and metabolic drug developed by Eli Lilly, is drawing intense attention from investors, physicians, and regulators alike, with some analysts projecting the broader obesity-drug market could event...
August 10, 2026: Compounded peptide injections recalled due to high endotoxin levels
Compounded Peptide Injections Recalled Over Endotoxin Contamination Concerns A recall of compounded peptide injection products has been issued after testing revealed elevated endotoxin levels, according to the Partnership for Safe Medicines, a nonprofit organization that tracks drug safety and coun...
Banned from sport over peptides: Kiwi world champion says he didn’t know he was doing anything wrong
New Zealand Athlete's Doping Ban Highlights Growing Peptide Regulatory Confusion A New Zealand world champion has been banned from competition after testing positive for banned peptides, telling reporters he was unaware he had done anything wrong, according to a report published by Stuff.
Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
Eli Lilly Escalates Legal Fight Against Peptide Vendors Selling Unapproved Retatrutide Eli Lilly and Company has filed lawsuits against a number of pharmacies and peptide vendors accused of manufacturing, marketing, and selling retatrutide, the pharmaceutical giant's experimental triple-hormone rec...
The 2026 GLP-1 Compounding Crackdown: A Pharmacist’s Guide
The 2026 GLP-1 Compounding Crackdown: What Pharmacists Need to Know Compounding pharmacies that have built substantial business lines around semaglutide and tirzepatide are bracing for intensified federal scrutiny as the calendar turns toward 2026, according to a report from Drug Topics titled "The...
One Year Later: Lessons in Compounding Compliance
Overview of the Regulatory Action The RealClearHealth commentary "One Year Later: Lessons in Compounding Compliance" arrives at a natural inflection point for the pharmacy compounding industry, marking roughly twelve months since the U.S.
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
This article is based on limited source information from a CBS News report referenced via Google News. Some contextual details reflect established public reporting on Eli Lilly's broader anti-counterfeiting and anti-diversion efforts regarding its weight-loss and diabetes drug portfolio.
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Lilly Sues Six Companies Over Alleged Illegal Sales of Experimental Obesity Drug Retatrutide Eli Lilly and Company has filed lawsuits against six companies accused of illegally selling retatrutide, the pharmaceutical giant's experimental triple-agonist obesity drug that has not yet received approva...
Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide
Eli Lilly Targets Gray-Market Sellers of Experimental Weight-Loss Drug Eli Lilly and Company has filed six separate lawsuits aimed at shutting down what the pharmaceutical giant describes as a burgeoning "black market" for retatrutide, an experimental triple-hormone receptor agonist still undergoin...
Eli Lilly targets alleged black market sales of its experimental GLP-1 drug
Eli Lilly Moves to Shut Down Alleged Black Market Sales of Experimental GLP-1 Drug Eli Lilly and Company has taken action against alleged black market sales of one of its experimental GLP-1 receptor agonist drugs, according to a report from The Hill.
Navigating Compounding Peptides and GLP-1s Through Regulations
Overview of the Regulatory Action The compounding of glucagon-like peptide-1 (GLP-1) receptor agonists and other peptide-based therapeutics has become one of the most closely watched flashpoints in pharmaceutical regulation over the past two years.
Growth Hormone Secretagogues Australia: TGA Classification and Legal Status
Growth Hormone Secretagogues in Australia: Prescription-Only Status Carries Serious Legal Risk for Unauthorized Importation Australians seeking growth hormone secretagogues such as Ipamorelin, CJC-1295, GHRP-2, GHRP-6, Sermorelin, and MK-677 (Ibutamoren) face a strict regulatory environment that cl...
F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom
California Pharmacy Regulators Weigh Response to Federal Peptide Prescribing Debate A recent advisory panel vote at the U.S.
Novo Nordisk wins Netherlands GLP-1 compounding lawsuit
Novo Nordisk Prevails in Netherlands Legal Battle Over Compounded GLP-1 Products Novo Nordisk has secured a legal victory in the Netherlands in a lawsuit concerning compounded versions of its GLP-1 receptor agonist medications, according to a report from pharmaphorum.
Troubling Findings in Study of GLP-1 Compounders
Troubling Findings in Study of GLP-1 Compounders A new study examining compounded versions of popular GLP-1 receptor agonist drugs has surfaced concerning findings, according to a report from MedPage Today, adding fresh scrutiny to an industry that expanded rapidly during a nationwide shortage of b...
August 3, 2026: Peptide vendor sentenced to six years for “incredible trail of harm”
Peptide Vendor Sentenced to Six Years in Federal Case Highlighting Dangers of Unregulated Peptide Market A peptide vendor has been sentenced to six years in federal prison following a prosecution that a federal judge reportedly described as leaving behind an "incredible trail of harm," according to...
The five risks of taking unapproved peptides
Partnership for Safe Medicines Report Highlights Growing Dangers in Unregulated Peptide Market The Partnership for Safe Medicines, a nonprofit coalition focused on drug safety and public health, has published a report identifying five key risks associated with the use of unapproved peptides — a r...
Peptides May Soon Be Legal. These Companies Are Ready To Cash In
Peptides May Soon Be Legal: Industry Players Position Themselves Ahead of Potential Regulatory Shift A new report from Forbes signals that the regulatory landscape for peptide-based products may be on the verge of significant change, with companies across the supplement, wellness, and pharmaceutica...
How wellness clinics bend the rules to supply unapproved peptides and anti-ageing injections
Wellness Clinics Skirt Regulatory Barriers to Sell Unapproved Peptides and Anti-Ageing Injections A growing network of wellness clinics across the country is exploiting regulatory loopholes to market and administer unapproved peptide therapies and anti-ageing injections, according to reporting from...
Medicare and Insurance Coverage for Peptide Therapy in 2026
Does insurance cover peptide therapy? Medicare and private insurance coverage for peptides depends on FDA approval status, medical necessity, and specific plan policies. This comprehensive guide explains when peptides are covered and how to maximize reimbursement.
EU Peptide Regulations: Country Guide
Overview of the Regulatory Action The European Union presents a complex regulatory landscape for peptides, differing significantly from the more unified approach observed in the United States under the FDA.
AKS Claims Allowed in D. Nev. Compounding Pharmacy Fraud Case
AKS Claims Proceed Against Compounding Pharmacy Accused of Kickbacks In a significant development for the pharmaceutical industry, a federal court in Nevada has ruled that claims under the Anti-Kickback Statute (AKS) can proceed against a compounding pharmacy accused of engaging in illegal kickback...
Health Law Alliance Appoints Dr. Martha Rumore as Of Counsel
Health Law Alliance Welcomes Compounding Expert Pharmacist-Attorney Dr. Martha Rumore as Of Counsel The Health Law Alliance has announced the appointment of Dr. Martha Rumore, a noted expert in pharmaceutical compounding and a licensed attorney, as Of Counsel.
Compounding Pharmacy Sues Lilly, Novo for GLP-1 Drug Monopoly
Lilly, Novo Sued Over GLP-1 Drug Dominance by Compounding Pharmacy In a significant legal development, pharmaceutical giants Eli Lilly and Novo Nordisk are facing a lawsuit from a compounding pharmacy that accuses them of monopolistic practices in the market for GLP-1 receptor agonists, a class of ...
Telehealth Exclusivity Wars Heat Up: GLP-1 Compounder Lawsuit
GLP-1 Compounder Lawsuit Highlights Telehealth Exclusivity Wars In a significant legal development affecting the peptide industry, a lawsuit involving a compounding pharmacy that produces GLP-1 (glucagon-like peptide-1) medications has brought to light the escalating competition over telehealth exc...
Telemedicine Peptide Clinics Face New Compliance Requirements
In the evolving landscape of healthcare, telemedicine has emerged as a pivotal component, offering patients unprecedented access to medical services.
Major Peptide Supplier Faces Regulatory Action: Industry Impact
The peptide industry, a cornerstone of modern biomedical research and therapeutic development, is experiencing a seismic shift as one of its major suppliers faces significant regulatory action.
International Peptide Regulations: How US Laws Compare
In the rapidly evolving world of biotechnology and pharmaceuticals, peptides are gaining unprecedented attention due to their potential in treating a range of conditions from metabolic disorders to cancer.
Peptide Market Shifts as Regulatory Pressure Increases
The peptide market, a cornerstone of modern pharmaceutical innovation, is experiencing a seismic shift as regulatory pressures intensify globally.
Compounding Pharmacy Industry Responds to GLP-1 Regulations
The compounding pharmacy industry is currently navigating a complex regulatory landscape, especially in light of recent changes to the guidelines surrounding the compounding of GLP-1 (glucagon-like peptide-1) receptor agonists.
Insurance Coverage for Peptide Therapy: Legal and Policy Updates
In recent years, peptide therapy has emerged as a promising treatment option in various medical fields, including endocrinology, dermatology, and neurology.